Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
Nicolette Stogios, Sri Mahavir Agarwal, Kateryna Maksyutynska et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated pharmacological interventions for weight reduction in patients with schizophrenia treated with antipsychotics. Among 95 studies involving 5898 participants, semaglutide was associated with the most significant weight reduction (mean difference -10.98 kg; 95% CI, -13.33 to -8.62) compared to placebo, indicating effective options for managing antipsychotic-induced weight gain.
Key findings
- Semaglutide led to a mean weight reduction of -10.98 kg compared to placebo.
- Liraglutide resulted in a mean weight reduction of -5.43 kg.
- Topiramate and metformin were associated with mean reductions of -3.95 kg and -3.86 kg, respectively.
- Clinically meaningful weight change of 5% or greater was observed with semaglutide and metformin.
Why it matters
Antipsychotic-induced weight gain is a significant concern in managing schizophrenia, contributing to cardiometabolic risks. Identifying effective pharmacological interventions can enhance patient outcomes and reduce associated health complications.